Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Corticotropin - Mallinckrodt

Drug Profile

Corticotropin - Mallinckrodt

Alternative Names: ACTH gel; Acthar; Acthar Gel; Adrenocorticotropin gel - Mallinckrodt; H.P. Acthar Gel; Repository corticotropin injection - Mallinckrodt

Latest Information Update: 04 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aventis Pharmaceuticals
  • Developer Mallinckrodt plc
  • Class Anterior pituitary hormones; Antiepileptic drugs; Corticosteroids; Hypothalamic hormones
  • Mechanism of Action Corticotropin receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Infantile spasms; Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Infantile spasms; Juvenile rheumatoid arthritis; Membranous glomerulonephritis; Multiple sclerosis; Nephrotic syndrome; Ocular inflammation; Polymyositis; Psoriatic arthritis; Rheumatoid arthritis; Sarcoidosis; Systemic lupus erythematosus
  • Phase II Amyotrophic lateral sclerosis; Scleritis
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 16 Jul 2019 Mallinckrodt terminates the phase IIb PENNANT trial in Amyotrophic lateral sclerosis in USA, Peru, Mexico, Colombia, Chile, Canada and Argentina (SC) (NCT03068754)
  • 01 Jan 2019 Phase-II clinical trials in Scleritis in USA (SC, Gel) (NCT03465111)
  • 22 Oct 2018 Pharmacodynamics data from a preclinical study in Arthritis presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top